Anaemia of cancer: Impact on patient fatigue and long-term outcome

Oncology

Volumn 69, Issue SUPPL. 2, 2005, Pages 2-7

  Harper, Peter ^a   Littlewood, Timothy ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Cancer; Fatigue; Mortality; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; METHOTREXATE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER MORTALITY; CANCER PATIENT; DYSTHYMIA; EXHAUSTION; FATIGUE; FRUSTRATION; HAIR LOSS; HEALTH SURVEY; HEMATOLOGIC DISEASE; HUMAN; LONG TERM CARE; MORTALITY; NAUSEA; PAIN; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; VOMITING;

ACTIVITIES OF DAILY LIVING; ANEMIA; ANEMIA, HYPOCHROMIC; COST OF ILLNESS; ERYTHROPOIETIN, RECOMBINANT; FATIGUE; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 27144507498     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088282     Document Type: Review

References (32)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Morère JF: Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer 2004;46:149-156.
3. Ludwig H: Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999;14(suppl 2):85-92.
4. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
5. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH: On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
6. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, Tattersall MH: On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-195.
7. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D: Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002;95:155-163.
8. Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK: Patient, care-giver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(suppl 2):4-12.
9. Curt GA, Breitbart W, Cella D, Groopman JE, Horning S, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ: Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353-360.
10. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N: Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 2000;11:971-975.
11. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998;25(suppl 7):43-46.
12. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 2001;91:2214-2221.
13. Van Belle SJ, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003;47:1-11.
14. Vaupel P, Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9(suppl 5):4-9.
15. Vaupel P, Hockel M: Tumor hypoxia and therapeutic resistance; in Nowrousian MR (ed): Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Berlin, Springer, 2002, pp 127-146.
16. Österborg A: Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol 1998:5(suppl 1):S47-S49.
17. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D; Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
18. Boogaerts M, Coiffier B, Kainz C; Epoetin beta QOL Working Group: Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-995.
19. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
20. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altes A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ; Darbepoetin Alfa 20000161 Study Group: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
21. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
22. Demetri GD, Kris M, Wade J, Degos L, Cella D: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
23. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
24. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
25. Cella D, Kallich J, McDermott A, Xu X: The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-986.
26. Glaser CM, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
27. Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimmig R, Dressler, Kentenich, Kohls A, Lichtenegger W, for the NOGGO-AGO-Intergroup: 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs without epoetin alfa for pts with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003;22:447 abstract 1798.
28. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A: Erythropoietin for patients with malignant disease (Cochrane Review). In: The Cochrane Library (Issue 4). Chichester, John Wiley & Sons Ltd, 2004.
29. Leyland-Jones B; BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
30. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;18:1255-1260.
31. Aapro M, Dunst J, Morère JF, Nowrousian MR, Huber M, Burger HU: Effect of NeoRecormon® (epoetin beta) on tumour progression and survival in patients with cancer: meta-analysis of controlled clinical trials. Ann Oncol 2004;15(suppl 3):abstract 841P.
32. Gillespie TW: Effects of cancer-related anemia on clinical and quality-of-life outcomes. Clin J Oncol Nurs 2002;6:206-211.